Pharmaceuticals

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities

Takeda's revamped oncology strategy prioritizes key tumors and innovative partnerships, enhancing growth prospects and market positioning.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Encouraging Interim Data for Innovative Skin Cancer Patch

Medicus Pharma’s SkinJect patch showed promising clinical clearance in Phase 2 interim data. Could this novel treatment be a game-changer in skin cancer care?

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

High Demand, Few Options: The Skin Cancer Treatment Gap

Basal Cell Carcinoma is 7x more common than melanoma, yet patients remain underserved. Sun and fair skin fuel its rise. Explore a rising need for treatments.

How to Invest in Medicus Pharma

Medicus Pharma (MDCX) is developing a breakthrough skin cancer patch targeting a $15B+ market. Strong IP, Phase 2 progress - learn how to invest.

Walgreens Boots Alliance Inc. (WBA): Upcoming Acquisition by Sycamore Partners

Sycamore Partners nears a $10B Walgreens buyout, potentially breaking up the retail giant. What it means for investors, market dynamics, and strategic shifts.

Hims & Hers Health (HIMS): Growth Amid Regulatory Challenges

Hims & Hers saw strong revenue growth but faces margin pressure and new FDA rules on weight-loss drugs. Can it adapt? Here’s what retail investors need to know.

Moderna Faces Challenges, MRNA Stock Continues YTD Decline

Moderna faces challenges with declining sales and pipeline delays, raising concerns for investors as it navigates its 2025 outlook in a shifting market.

SelectQuote Reports Impressive Q2 Growth

SelectQuote's Q2 FY2025 performance highlights significant revenue growth, soaring net income, and strategic investments, reinforcing its market strength and potential.

Shares Soar as GH Research Unveils Promising Drug Trial

GH Research PLC's stock soared 89% after promising results for GH001, an innovative therapy for treatment-resistant depression. Explore the potential.

Thermo Fisher Posts Strong Q4 Earnings Boosting Stock

Thermo Fisher Scientific's Q4 results show increased earnings and revenue, with strong product launches and a positive outlook for future growth.

Akero (AKRO) Stock Surges on Promising Drug Results

Akero Therapeutics' efruxifermin shows promising results in treating liver cirrhosis, driving stock surges and revealing new investment prospects in biotech.

J&J Achieves Strong Q4 Performance

Johnson & Johnson's Q4 results reveal strong revenue growth, driven by Darzalex sales, and an optimistic outlook for 2025 amidst strategic acquisitions.